Preview

Современная ревматология

Расширенный поиск

Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов

https://doi.org/10.14412/1996-7012-2020-3-7-18

Полный текст:

Аннотация

Псориаз (Пс), псориатический артрит (ПсА) и воспалительные заболевания кишечника (ВЗК) характеризуются прогрессирующим течением и нередко приводят к инвалидизации, поэтому важными задачами являются их ранняя диагностика с оценкой клинического фенотипа и факторов неблагоприятного прогноза и своевременное начало терапии. В статье приводятся согласованная позиция экспертов по определению ранней стадии Пс, ПсА и ВЗК, цели терапии и основные факторы неблагоприятного прогноза течения этих заболеваний, представлено обоснование раннего применения генно-инженерных биологических препаратов у пациентов с иммуновоспалительной патологией.

Об авторах

Д. И. Абдулганиева
ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России
Россия

Диана Ильдаровна Абдулганиева

420012, Казань, ул.Бутлерова, 49



А. Л. Бакулев
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России
Россия
410012, Саратов, ул. Большая Казачья, 112


Е. А. Белоусова
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»
Россия

Елена Александровна Белоусова

129110, Москва, ул. Щепкина, 61/2



А. В. Веселов
ФГБУ «Национальный медицинский исследовательский центр колопроктологии им. А.Н. Рыжих» Минздрава России
Россия
123423, Москва, ул. Саляма Адиля, 2


Т. В. Коротаева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

Татьяна Викторовна Коротаева

115522, Москва, Каширское шоссе, 34А



А. М. Лила
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия
115522, Москва, Каширское шоссе, 34А
125993, Москва, ул. Баррикадная, 2/1, стр. 1


Е. Ю. Логинова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Е. В. Соколовский
кафедра дерматовенерологии с клиникой ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России
Россия
197022, Санкт-Петербург, ул. Льва Толстого, 6–8


М. М. Хобейш
кафедра дерматовенерологии с клиникой ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России
Россия

Марианна Михайловна Хобейш

197022, Санкт-Петербург, ул. Льва Толстого, 6–8



М. В. Шапина
ФГБУ «Национальный медицинский исследовательский центр колопроктологии им. А.Н. Рыжих» Минздрава России
Россия
123423, Москва, ул. Саляма Адиля, 2


О. Б. Щукина
Городской центр диагностики и лечения воспалительных заболеваний кишечника, Санкт-Петербургское ГУЗ «Городская клиническая больница № 31»
Россия
197110, Санкт-Петербург, проспект Динамо, 3


Литература

1. Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths G. Ashcroft D. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020 May 28;369:m1590. doi: 10.1136/bmj.m1590.

2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007 Jul 21;370(9583):263-71. doi: 10.1016/S01406736(07)61128-3.

3. Olivieri I, D'Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014 Sep; 10(9):531-42. doi: 10.1038/nrrheum.2014.106. Epub 2014 Jul 8.

4. Heijde D, Gladman D, Kavanaugh A, Mease P. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020 Feb 3;22(1):18. doi: 10.1186/s13075-020-2103-8.

5. Colombel JF, D'haens G, Lee WJ, et al. Outcomes and Strategies to Support a Treatto-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020 Feb 10;14(2):254-66. doi: 10.1093/ecco-jcc/jjz131.

6. Kemp K, Dibley L, Chauhan U, et al. Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis. J Crohns Colitis. 2018 Jun 28;12(7): 760-776. doi: 10.1093/ecco-jcc/jjy020.

7. Drescher H, Lissoos T. Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers. J Nurse Pract. 2019;15:e676-e681

8. Theede K, Burisch J. Defining success in treating patients with inflammatorybowel disease. Expert Rev Clin Immunol. 2017 Jul;13(7):645-47. doi: 10.1080/1744666X.2017.1317594. Epub 2017 Apr 17.

9. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017 Feb;152(2):351-61.e5. doi: 10.1053/j.gastro.2016.09.046. Epub 2016 Oct 5.

10. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9. doi: 10.1046/j.1087-0024.2003.09102.x.

11. Springate DA, Parisi R, Kontopantelis E, et al. Incidence, prevalence and mortality of patients with psoriasis: a U.K. populationbased cohort study. Br J Dermatol. 2017 Mar; 176(3):650-58. doi: 10.1111/bjd.15021. Epub 2016 Dec 22.

12. Fernandez-Armenteros JM, GomezArbones X, Buti-Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):128-35. doi: 10.1111/jdv.15159. Epub 2018 Jul 17.

13. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015 Feb;74(2):326-32. doi: 10.1136/annrheumdis-2014-205675. Epub 2014 Oct 28.

14. Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: A UK population-based cohort study. Rheumatology (Oxford). 2014 Feb;53(2):346-52. doi: 10.1093/rheumatology/ket343. Epub 2013 Oct 31.

15. Xue Y, Jiang L, Cheng Q, et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One. 2012;7(10):e46740. doi: 10.1371/journal.pone.0046740. Epub 2012 Oct 29.

16. Peluso R, Iervolino S, Vitiello M, et al. Extra-articular manifestations in psoriatic arthritispatients. Clin Rheumatol. 2015 Apr; 34(4):745-53. doi: 10.1007/s10067-014-2652-9. Epub 2014 May 8.

17. Bernstein C, Benchimol E, Bitton A, et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S73-S80. doi: 10.1093/jcag/gwy053. Epub 2018 Nov 2.

18. Halling ML, Kjeldsen J, Knudsen T, et al. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017 Sep 7;23(33):6137-46. doi: 10.3748/wjg.v23.i33.6137.

19. Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study. PLoS One. 2013; 8(2):e56944. doi: 10.1371/journal.pone.0056944. Epub 2013 Feb 15.

20. Olivieri I, Padula A, D'Angelo S, et al. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009 Aug;83:28-9. doi: 10.3899/jrheum.090218.

21. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007 Sep;1(1):10-20. doi: 10.1016/j.crohns.2007.06.005.

22. Белоусова ЕА. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445–63.

23. Щукина ОБ. Дифференциально-диагностические и прогностические критерии клинических форм болезни Крона. Автореф. дисс. докт. мед. наук. Санкт-Петербург; 2017. 37 с.

24. Fiorino G, Morin M, Bonovas S, et al. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. J Crohns Colitis. 2017 Mar 1;11(3):274-80. doi: 10.1093/ecco-jcc/jjw185.

25. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015 Jun;74(6):1045-50. doi: 10.1136/annrheumdis-2013-204858. Epub 2014 Feb 13.

26. Tillett W, Jadon D, Shaddick G, et al. Smoking and Delay to Diagnosis Are Associated With Poorer Functional Outcome in Psoriatic Arthritis. Ann Rheum Dis. 2013 Aug;72(8):1358-61. doi: 10.1136/annrheumdis2012-202608. Epub 2013 Jan 3.

27. Fu Y, Lee CH, Chi CC. Association of Psoriasis with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018 Dec 1;154(12):1417-23. doi: 10.1001/jamadermatol.2018.3631.

28. Ko JS, Uberti G, Napekoski K, et al. Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 yeras. J Cutan Pathol. 2016 Nov;43(11):946-55. doi: 10.1111/cup.12777. Epub 2016 Aug 26.

29. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct;20 Suppl 4:36-42. doi: 10.1111/j.1365-2036.2004.02044.x.

30. Burisch J, Vind I, Prosberg M, et al. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. J Crohns Colitis. 2017 Oct 1;11(10):1200-04. doi: 10.1093/ecco-jcc/jjx066.

31. Дерматовенерология, Федеральные клинические рекомендации. 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд. Москва: Деловой экспресс; 2016. 768 с.

32. Gladman D, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64(Suppl 2):ii14-ii17. doi: 10.1136/ard.2004.032482;

33. Zhu T, Li E, Tam LS. Cardiovascular Risk in Patients with Psoriatic Arthritis. Int J Rheumatol. 2012;2012:714321. doi: 10.1155/2012/714321. Epub 2012 May 8.

34. Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019 Mar;15(3):153-66. doi: 10.1038/s41584-019-0175-0.

35. Насонов ЕЛ, Коротаева ТВ, Лила АМ. Можно ли предотвратить развитие псориатического артрита у пациентов с псориазом? Научно-практическая ревматология. 2019;57(3):250–4. doi: 10.14412/1995-4484-2019250-254

36. Абдулганиева ДИ. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению ГИБП у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;12(3):4-18. doi: 10.14412/1996-70122018-3-4-18

37. Чамурлиева МН, Коротаева ТВ, Логинова ЕЮ, Баткаев ЭА. Алгоритм диагностики псориатического артрита в клинической практике дерматолога. Российский журнал кожных и венерических болезней. 2016;19(1):36-40.

38. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003 Dec;42(12): 1460-8. doi: 10.1093/rheumatology/keg384. Epub 2003 Oct 1.

39. Lubrano E, Mesina F, Caporali R. Clinical remission in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. SepOct 2018;36(5):900-10. Epub 2018 Mar 16.

40. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27.

41. Peyrin-Biroulet L. Why should we define and target early Crohn's disease? Gastroenterol Hepatol (N Y). 2011 May;7(5):324-6.

42. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a populationbased inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431-40. doi: 10.1080/00365520802600961.

43. Andrews JM. Le plus ca change: why we need better biomarkers to predict outcomes in ulcerative colitis. J Gastroenterol Hepatol. 2011 Jul;26(7):1085-6. doi: 10.1111/j.14401746.2011.06754.x.

44. Gadman D. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012 May;38(2): 373-86. doi: 10.1016/j.rdc.2012.05.005. Epub 2012 Jun 29.

45. Aletaha D, Eberl G, Nell VP, et al. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis. 2002 Jul;61(7):630-4. doi: 10.1136/ard.61.7.630.

46. Логинова ЕЮ, Коротаева ТВ. Ранний псориатический артрит. Научно-практическая ревматология. 2008;46(6):47-55. doi: 10.14412/1995-4484-2008-490

47. Jadon DR, Sengupta R, Nightingale A, et al. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017 Apr;76(4):701-07. doi: 10.1136/annrheumdis-2016-209853. Epub 2016 Dec 2.

48. Elnady B, El Shaarawy N, Dawoud NM, et al. Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years. Clin Rheumatol. 2019 Jun;38(6):1627-35. doi: 10.1007/s10067-01904445-0. Epub 2019 Feb 12.

49. Peyrin-Biroulet L, Billioud V, D'Haens G, et al. Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process . Am J Gastroenterol. 2012 Dec;107(12):1770-6. doi: 10.1038/ajg.2012.117.

50. Бакулев АЛ. Псориаз: клинические особенности, факторы риска и ассоциированные коморбидные состояния. Клиническая фармакология и терапия. 2019;27(1):35–9.

51. Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: A clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002 Jun;46(6):867-73. doi: 10.1067/mjd.2002.120470.

52. Singh S, Kalb RE, de Jong EM, Shear NH, et al. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol. 2018 Dec;19(6):879-86. doi: 10.1007/s40257018-0388-z.

53. Sakai R, Matsui S, Fukushima M, et al. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005;211(2):103-6. doi: 10.1159/000086437.

54. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: Evidence from the psocare project. Dermatology. 2008;217(4):365-73. doi: 10.1159/000156599. Epub 2008 Sep 23.

55. Ogdie A. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. Curr Rheumatol Rep. 2015 Oct; 17(10):64. doi: 10.1007/s11926-015-0540-1

56. Eder L, Haddad A, Rosen C. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis. Arthritis Rheumatol. 2016 Apr;68(4):915-23. doi: 10.1002/art.39494.

57. Yan D, Ahn R, Leslie S, Liao W. Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis. Dermatol Ther (Heidelb). 2018 Dec;8(4):593-604. doi: 10.1007/s13555-0180266-x. Epub 2018 Oct 20.

58. Коротаева ТВ. Псориатический артрит. Клинические рекомендации по диагностике и лечению. Современная ревматология. 2018;12(2):22-35. doi: 10.14412/1996-70122018-2-22-35

59. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.

60. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020 Jan 1;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180

61. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec; 68(Suppl 3):s1-s106. doi: 10.1136/gutjnl2019-318484. Epub 2019 Sep 27.

62. Gomollon F, Dignass A, Annese V, et al. 3 rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan; 11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.

63. Reinisch W, Reinink AR, Higgins PD. Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):635-42. doi: 10.1016/j.cgh.2014.03.037. Epub 2014 Jun 2.

64. Feuerstein JD, Isaacs KL, Schneider Y, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020 Apr;158(5):1450-61. doi: 10.1053/j.gastro.2020.01.006. Epub 2020 Jan 13.

65. Dias CC, Rodrigues PP, da Costa-Pereira A, et al. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015 Feb;9(2): 156-63. doi: 10.1093/ecco-jcc/jju016.

66. Ивашкин ВТ, Шелыгин ЮА, Белоусова ЕА и др. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7-36.

67. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets inInflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25.

68. Coates L, Lubrano E, Perrotta F, et al. What Should Be the Primary Target of «Treat to Target» in Psoriatic Arthritis? J Rheumatol. 2019 Jan;46(1):38-42. doi: 10.3899/jrheum.180267. Epub 2018 Sep 15.

69. Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR ). Br J Dermatol. 2020 May;182(5):1158-66. doi: 10.1111/bjd.18333. Epub 2019 Sep 10.

70. Takeshita J. Taking aim at identifying treatment targets for psoriasis. Br J Dermatol. 2020 May;182(5):1075-76. doi: 10.1111/bjd.18635.

71. Saber T, Renard G, Lynch B, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):R94. doi: 10.1186/ar3021. Epub 2010 May 18.

72. Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.

73. Kavanaugh A, van der Heijde D, Beutler A, et al. Radiographic progression of patients with Psoriatic Arthritis Who achieve Minimal disease activity in response to Golimumab therapy: results through 5 years of a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2016 Feb;68(2): 267-74. doi: 10.1002/acr.22576.

74. Mease PJ, Kavanaugh A, Coates LC, et al. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

75. Coates LC, Mease PJ, Gossec L, et al. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10): 1529-35. doi: 10.1002/acr.23537. Epub 2018 Sep 1.

76. Van Mens LJ, de Jong HM, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a doubleblind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019 May; 78(5):610-16. doi: 10.1136/annrheumdis2018-214746. Epub 2019 Feb 26.

77. Коротаева ТВ, Логинова ЕЮ, Гетия ТС, Насонов ЕЛ. Результаты применения стратегии «Лечение до достижения цели» у больных ранним псориатическим артритом через 1 год после начала терапии: данные исследования РЕМАРКА. Терапевтический архив. 2018;90(5):22-9.

78. Gulliver W, Lynde C, Dutz JP, et al. Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis. J Cutan Med Surg. 2015 Jan-Feb;19(1):22-7. doi:10.2310/7750.2014.13151. Epub 2015 Jan 1.

79. http://cr.rosminzdrav.ru/schema.html?id=866#/text

80. Carretero G, Puig L, Carrascosa JM, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018 Jun;29(4): 334-46. doi: 10.1080/09546634.2017.1395794. Epub 2017 Nov 21.

81. Papp K, Gulliver W, Lynde C, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. Jul-Aug 2011;15(4):210-9. doi: 10.2310/7750.2011.10066.

82. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011 Jan;303(1):1-10. doi: 10.1007/s00403-010-1080-1. Epub 2010 Sep 21.

83. Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013 May;54(2):148-54

84. Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013 Oct; 104(8):694-709. doi: 10.1016/j.adengl.2013.04.013. Epub 2013 Sep 7.

85. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-36. doi: 10.1111/bjd.15665

86. Amatore F. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):464-83. doi: 10.1111/jdv.15340. Epub 2019 Feb 22.

87. Gossec L, McGonagle D, Korotaeva T, et al. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018;45(1):6-13. doi:10.3899/jrheum.170449. Epub 2017 Nov 15.

88. Allen PB, Olivera P, Emery P, et al. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 Apr;45(8): 1058-72. doi: 10.1111/apt.13995. Epub 2017 Mar 1.

89. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152.

90. Danese S, Allez M, van Bodegraven AA, et al. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Dig Dis. 2019;37(4):266-83. doi: 10.1159/000496739. Epub 2019 Feb 6.

91. Ungaro R, Colombel JF, Lissoos T, et al. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019 Jun;114(6):874-83. doi: 10.14309/ajg.0000000000000183

92. Schoels MM, Landesmann U, Alasti F, et al. Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. Rheumatology (Oxford). 2018 Jun 1;57(6):969-76. doi: 10.1093/rheumatology/key004.

93. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 7;386(10006):1825-34. doi: 10.1016/S0140-6736(15)00068-9. Epub 2015 Sep 3.

94. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 May; 68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.

95. Schoels M, Landesmann U, Alasti F, et al. Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. Rheumatology (Oxford). 2018 Jun 1;57(6):969-76. doi: 10.1093/rheumatology/key004.

96. Thompson W, Argaez C. Early biologic treatment versus conventional treatment for the management of Crohn's Disease: A review of comparative clinical effectiveness and cost-effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Feb 13.

97. Ивашкин ВТ, Шелыгин ЮА, Абдулганиева ДИ и др. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38.

98. Ko CW, Singh S, Feuerstein JD, et al.; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2019 Feb;156(3):748-64

99. Singh S, Kalb RE, de Jong EM, et al. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol. 2018 Dec;19(6):879-86. doi: 10.1007/s40257018-0388-z.

100. Коротаева ТВ, Логинова ЕЮ, Каратеев ДЕ и др. Стратегия «Лечение до достижения цели» при раннем псориатическом артрите (предварительные результаты исследования РЕМАРКА). Научнопрактическая ревматология. 2014;52(4):376-80. doi: 10.14412/1995-4484-2014-376-380

101. Loginova EY, Korotaeva TV , Koltakova A, Gubar E. SAT0384. Comparative analysis of frequency and timing of minimal disease activity (MDA) attainment in early and long-term psoriatic arthritis (PSA) patients (PTS) after biological (B) dmards treatment initiation in clinical practice: russian PSA Ann Rheum Dis. 2019; 78(Suppl 2):1276_registry (RU-PSART) data.

102. Shergill A, Terdiman J. Controversies in the treatment of Crohn's disease: The case for an accelerated step-up treatment approach. World J Gastroenterol. 2008 May 7;14(17): 2670-7. doi: 10.3748/wjg.14.2670.

103. Pappu R, Ramirez-Carrozzi V, Ota N, et al. The IL-17 family cytokines in immunity and disease. J Clin Immunol. 2010 Mar;30(2): 185-95. doi: 10.1007/s10875-010-9369-6. Epub 2010 Feb 23.

104. Круглова ЛС, Львов АН, Каграманова АВ, Князев ОВ. Псориаз и воспалительные заболевания кишечника: пути патогенеза и вопросы выбора генно-инженерных препаратов (обзор литературы). Альманах клинической медицины. 2019;47(6):568-78.

105. Hindryckx P, Novak G, Bonovas S, et al. Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. Clin Pharmacol Ther. 2017 Oct;102(4): 633-41. doi: 10.1002/cpt.791. Epub 2017 Aug 16.

106. Papa Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf. 2016;15(4):493-501. doi: 10.1517/14740338.2016.1145653. Epub 2016 Feb 19.

107. Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep. 2019 Jan 11;21(2):1. doi: 10.1007/s11894-0190669-6.

108. Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014 Jul;171(1):137-47. doi: 10.1111/bjd.13013. Epub 2014 Jul 16.

109. Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015 Jul;14(7):706-14.

110. Vilarrasa E, Notario J, Bordas X, et al. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016 Jun;74(6):1066-72. doi: 10.1016/j.jaad.2016.01.037. Epub 2016 Mar 19.

111. Iskandar IY, Ashcroft DM, Warren RB, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015 Aug;173(2):510-8. doi: 10.1111/bjd.13908. Epub 2015 Jul 6.

112. Van den Reek JM, Zweegers J, Kievit W, et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014 Nov;171(5):1189-96. doi: 10.1111/bjd.13087. Epub 2014 Oct 3.

113. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011 May;164(5):1091-6. doi: 10.1111/j.1365-2133.2011.10213.x. Epub 2011 Apr 11.

114. Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018 Feb; 178(2):509-519. doi: 10.1111/bjd.16102

115. Lunder T, Zorko MS, Kolar NK, et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019 Jun;58(6):631-41.

116. Ko Y. Presentation at ECCO 2020. P361.

117. Savage L, Goodfield M, Horton L, et al. Regression of Peripheral Subclinical Enthesopathy in Therapy – Naive Patients Treated With Ustekinumab for Moderate to – Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. Arthritis Rheumatol. 2019 Apr;71(4):626-31. doi: 10.1002/art.40778. Epub 2019 Mar 4

118. Kampylafka E, Simon D, d'Oliveira I, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019 Jul 26;21(1):178. doi: 10.1186/s13075019-1957-0.

119. Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018 Feb; 19(1):1-13. doi: 10.1007/s40257-017-0328-3.

120. Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018 Feb; 78(2):383-394. doi: 10.1016/j.jaad.2017.06.043.

121. Varu A, Wilson FR, Dyrda P, et al. Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. Curr Med Res Opin. 2019 May;35(5):733-56. doi: 10.1080/03007995.2019.1580094. Epub 2019 Mar 20.

122. Инструкция по медицинскому применению лекарственного препарата Стелара. Министерство здравоохранения Российской Федерации ЛСР-006465/09-23.04.2020, ЛП-005728-24.05.2020.

123. Dures E, Taylor J, Shepperd S, et al. Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis. Ann Rheum Dis. 2020 Aug;79(8):1031-36. doi: 10.1136/annrheumdis-2020-217301. Epub 2020 May 18.


Для цитирования:


Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А., Веселов А.В., Коротаева Т.В., Лила А.М., Логинова Е.Ю., Соколовский Е.В., Хобейш М.М., Шапина М.В., Щукина О.Б. Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов. Современная ревматология. 2020;14(3):7-18. https://doi.org/10.14412/1996-7012-2020-3-7-18

For citation:


Abdulganieva D.I., Bakulev A.L., Belousova E.A., Veselov A.V., Korotaeva T.V., Lila A.M., Loginova E.Yu., Sokolovskiy E.V., Khobeish M.M., Shapina M.V., Shchukina O.B. Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion. Modern Rheumatology Journal. 2020;14(3):7-18. (In Russ.) https://doi.org/10.14412/1996-7012-2020-3-7-18

Просмотров: 660


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)